Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
Sponsor: Novartis Pharmaceuticals
Summary
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2023-03-08
Completion Date
2025-07-01
Last Updated
2026-07-09
Healthy Volunteers
Yes
Conditions
Interventions
QCZ484
doses of 50, 150, 300 or 600 mg via subcutaneous injection
Placebo
via subcutaneous injection
Locations (4)
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Morayfield, Queensland, Australia
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Auckland, New Zealand